Skip to main content
S&P 5007,623.68-0.52%DOW52,215.16-1.23%NASDAQ25,955.34-0.21%BTC$80,645.00-0.98%ETH$2,373.55-0.82%GOLD$4,010.00-1.24%OIL$103.44+3.99%
Smart Investors Daily
SID Premium
VA

NASDAQ · VALN

Valneva SE

Healthcare · Biotechnology

$5.26

Down-$0.10 (-1.87%)

Updated Oct 25, 2026, 3:37 AM

SID Score

3.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
752.57M
P/E ratio
-9.07
Dividend yield
0.00%
52-week range
$4.75 – $12.18
Volume
6.41K
Avg. volume
41.67K

Price performance · VALN

VALN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 23, 2026

VALN closed at $5.26 after 20 trading sessions, down 18.70% for the selected period.

Last close
$5.26
Period change
-18.70%
Period low
$5.26
Period high
$6.47
Daily close
View OHLC price history
VALN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 23, 2026$5.2573$5.295$5.25$5.266.41K
Oct 22, 2026$5.49$5.61$5.31$5.3622.62K
Oct 21, 2026$5.75$5.75$5.5301$5.56137.26K
Oct 20, 2026$5.54$5.84$5.54$5.6913.1K
Oct 19, 2026$5.53$5.53$5.40$5.519.14K
Oct 16, 2026$5.87$5.87$5.58$5.619.48K
Oct 15, 2026$5.84$5.91$5.77$5.918.68K
Oct 14, 2026$5.66$5.73$5.61$5.6622.52K
Oct 13, 2026$5.89$5.89$5.55$5.5628.75K
Oct 12, 2026$5.86$5.96$5.85$5.9310.52K
Oct 9, 2026$5.81$5.81$5.73$5.785.61K
Oct 8, 2026$5.612$5.74$5.612$5.6911.26K
Oct 7, 2026$5.8676$5.99$5.8676$5.8726.27K
Oct 6, 2026$6.04$6.04$5.78$5.8619.06K
Oct 5, 2026$5.89$5.985$5.70$5.81569.38K
Oct 2, 2026$5.84$5.8931$5.73$5.7439.84K
Oct 1, 2026$6.05$6.075$5.90$5.9034.51K
Sep 30, 2026$6.19$6.27$6.16$6.1855.84K
Sep 29, 2026$6.36$6.36$6.125$6.149.63K
Sep 28, 2026$6.25$6.49$6.225$6.4721.57K

Latest VALN news

The latest Smart Investors Daily articles mentioning VALN.

Stock researchCompany · Overview

VALN research

Overview

Company profile and research snapshot.

Company profile

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$14.00
Implied upside
—
Analysts
—
VALN recent ratings
DateFirmRatingTarget
Sep 23, 2026FIRST BERLIN EQUITY RESEARCHBuy—
Aug 14, 2026STIFEL EUROPEBuy—
Aug 6, 2026PORTZAMPARC BNP PARIBASBuy—
Jul 13, 2026FIRST BERLIN EQUITY RESEARCHBuy—
Jul 12, 2026FIRST BERLIN EQUITY RESEARCHBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 5, 2026

Declaration of shares and voting rights - Status as of September 30, 2026

VALNEVA Declaration of shares and voting rights Status as of September 30, 2026__________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 LyonRegulated market of Euronext Paris - Compartment B Declaration date: October 5, 2026 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Descr

Yahoo · Sep 15, 2026

Pfizer (PFE), Valneva (VALN) Lyme Vaccine Moves to EMA Review Despite Phase 3 Caveat

Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies’ experimental Lyme disease vaccine candidate, and will now begin the official review. For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French […]

Yahoo · Sep 7, 2026

Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva

Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By